drugset
drugset / Trial / NCT03519256

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

NCT03519256 ↗

Phase 2 Terminated 142 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.

Timeline

Start
2018-08-02
Primary completion
2022-08-22
Completion
2022-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject BCG Unknown — Intravenous
Subject LINRODOSTAT Small molecule — —
Subject Nivolumab Monoclonal antibody — —

Indications

urinary bladder cancer